Certain Stock Options of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024.
June 31, 2024
Share
Certain Stock Options of Gritstone bio, Inc. are subject to a Lock-Up Agreement Ending on 1-JUN-2024. These Stock Options will be under lockup for 61 days starting from 1-APR-2024 to 1-JUN-2024.
Details:
Executive officers and directors have agreed, subject to certain exceptions, not to (i) offer, sell, contract to sell, pledge, grant any option to purchase, lend or otherwise dispose of any shares of common stock, or any options or warrants to purchase any shares of common stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of common stock (such options, warrants or other securities, collectively, ?Derivative Instruments?), (ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition, or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any shares of our common stock or Derivative Instruments, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of our common stock or other securities, in cash or otherwise, or (iii) otherwise publicly announce any intention to engage in or cause any action or activity described in clause (i) above or transaction or arrangement described in clause (ii) above, without the prior written consent of TD Securities (USA) LLC and Evercore Group L.L.C. for a period of 60 days after the date of the pricing of the offering (the ?Lock-Up Period?). However, we may sell shares of our common stock under our ATM Offering following this offering.
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.